Current and historical daily PE Ratio for CHGCY (
Chugai Pharmaceutical Co Ltd
) from 2008 to Jun 09 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Chugai Pharmaceutical stock (CHGCY) PE ratio as of Jun 09 2024 is 23.98.
More Details
Chugai Pharmaceutical Co Ltd (CHGCY) PE Ratio (TTM) Chart
Chugai Pharmaceutical Co Ltd (CHGCY) PE Ratio (TTM) Historical Data
View and export this data going back to 2008. Start your Free Trial
Total 1246
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Chugai Pharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-09 | 22.1 | 2024-04-05 | 26.4 |
| 2024-06-07 | 22.1 | 2024-04-04 | 26.6 |
| 2024-06-06 | 22.6 | 2024-04-03 | 27.1 |
| 2024-06-05 | 22.7 | 2024-04-02 | 26.8 |
| 2024-06-04 | 22.5 | 2024-04-01 | 27.6 |
| 2024-06-03 | 22.4 | 2024-03-28 | 28.1 |
| 2024-05-31 | 22.4 | 2024-03-27 | 28.1 |
| 2024-05-30 | 21.9 | 2024-03-26 | 28.1 |
| 2024-05-29 | 21.6 | 2024-03-25 | 27.7 |
| 2024-05-28 | 22.1 | 2024-03-22 | 27.7 |
| 2024-05-24 | 22.1 | 2024-03-21 | 28.0 |
| 2024-05-23 | 22.1 | 2024-03-20 | 29.0 |
| 2024-05-22 | 22.6 | 2024-03-19 | 28.9 |
| 2024-05-21 | 23.5 | 2024-03-18 | 29.5 |
| 2024-05-20 | 23.6 | 2024-03-15 | 28.9 |
| 2024-05-17 | 23.5 | 2024-03-14 | 29.4 |
| 2024-05-16 | 23.2 | 2024-03-13 | 30.1 |
| 2024-05-15 | 23.0 | 2024-03-12 | 31.3 |
| 2024-05-14 | 22.5 | 2024-03-11 | 31.5 |
| 2024-05-13 | 23.1 | 2024-03-08 | 31.5 |
| 2024-05-10 | 23.2 | 2024-03-07 | 31.0 |
| 2024-05-09 | 23.4 | 2024-03-06 | 30.8 |
| 2024-05-08 | 23.3 | 2024-03-05 | 30.0 |
| 2024-05-07 | 23.5 | 2024-03-04 | 29.8 |
| 2024-05-06 | 24.5 | 2024-03-01 | 29.3 |
| 2024-05-03 | 24.4 | 2024-02-29 | 28.6 |
| 2024-05-02 | 24.2 | 2024-02-28 | 28.3 |
| 2024-05-01 | 23.3 | 2024-02-27 | 28.6 |
| 2024-04-30 | 23.3 | 2024-02-26 | 28.6 |
| 2024-04-29 | 23.0 | 2024-02-23 | 27.1 |
| 2024-04-26 | 22.6 | 2024-02-22 | 26.8 |
| 2024-04-25 | 22.9 | 2024-02-21 | 28.1 |
| 2024-04-24 | 23.5 | 2024-02-20 | 27.9 |
| 2024-04-23 | 24.6 | 2024-02-16 | 28.1 |
| 2024-04-22 | 24.4 | 2024-02-15 | 27.5 |
| 2024-04-19 | 23.3 | 2024-02-14 | 27.1 |
| 2024-04-18 | 23.9 | 2024-02-13 | 27.0 |
| 2024-04-17 | 24.0 | 2024-02-12 | 26.3 |
| 2024-04-16 | 24.4 | 2024-02-09 | 26.1 |
| 2024-04-15 | 23.9 | 2024-02-08 | 25.9 |
| 2024-04-12 | 24.3 | 2024-02-07 | 25.1 |
| 2024-04-11 | 25.1 | 2024-02-06 | 24.8 |
| 2024-04-10 | 24.9 | 2024-02-05 | 24.6 |
| 2024-04-09 | 26.0 | 2024-02-02 | 25.1 |
| 2024-04-08 | 26.0 | 2024-02-01 | 26.2 |
Chugai Pharmaceutical Co Ltd (CHGCY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Chugai Pharmaceutical Co Ltd
NAICS : 325412
ISIN : US1712691039
Share Class Description:
CHGCY: ADRDescription
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19 patients.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers